Rates of HCV Treatment Eligibility Among HCV-Monoinfected and HCV/HIV-Coinfected Patients in Tertiary Care Referral Centers
about
Analysis of a summary network of co-infection in humans reveals that parasites interact most via shared resourcesBarriers to hepatitis C antiviral therapy in HIV/HCV co-infected patients in the United States: a reviewVirologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings.The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis.Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone maintenance therapy.Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfected patients.Systematic review of the pharmacological treatment of alcohol use disorders in individuals infected with hepatitis C.Non-initiation of hepatitis C virus antiviral therapy in patients with human immunodeficiency virus/hepatitis C virus co-infection.HIV and liver disease forum: conference proceedingsLiver fibrosis progression in hepatitis C virus infection after seroconversionTreatment of genotype 1 HCV infection in the HIV coinfected patient in 2014.Depression in HIV and HCV co-infected patients: a systematic review and meta-analysis.Tricyclic antidepressant use and the risk of fibrosis progression in hepatitis C-infected persons: Results from ERCHIVES.
P2860
Q24568161-FD79B0CB-6CBB-48A5-B33C-E5E6596D7B8AQ27010548-A2C0C862-6A27-4F09-8F7E-2F652A8A8A17Q33419423-CE62FB39-6426-442D-B2C4-D35AC8FE16A5Q33837518-4F523384-EE96-4AC6-BC10-56015D8019F6Q34417838-46CD4FCF-5BF5-4554-8C1B-BC35CC70F5A0Q34749550-03DBACA1-D686-4AC8-8289-747A9125ED59Q36259199-703ACA24-8E3C-4240-90B9-0524C28151C7Q36654120-189D6953-58E0-4B3B-B7CA-BC6137E37918Q36835630-F72E9FA3-C353-451E-8867-CB1A466C1D79Q37244507-9D5A88C6-3659-47AF-BC43-3B08BD178C88Q38165816-4B72B918-3C7E-419E-933D-86D608676A57Q39093985-D30DE1BB-055D-4948-957C-B0FAF2BB468DQ52686485-BA7F4C7E-40F3-434D-AD55-3593B5BF93A6
P2860
Rates of HCV Treatment Eligibility Among HCV-Monoinfected and HCV/HIV-Coinfected Patients in Tertiary Care Referral Centers
description
2009 թուականին հրատարակուած գիտական յօդուած
@hyw
2009 թվականին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2009
@ast
scientific article (publication date: 2009)
@en
vědecký článek
@cs
wetenschappelijk artikel (gepubliceerd in 2009)
@nl
wissenschaftlicher Artikel
@de
наукова стаття, опублікована у 2009
@uk
مقالة علمية (نشرت عام 2009)
@ar
name
Rates of HCV Treatment Eligibi ...... Tertiary Care Referral Centers
@ast
Rates of HCV Treatment Eligibi ...... Tertiary Care Referral Centers
@en
Rates of HCV Treatment Eligibi ...... Tertiary Care Referral Centers
@nl
type
label
Rates of HCV Treatment Eligibi ...... Tertiary Care Referral Centers
@ast
Rates of HCV Treatment Eligibi ...... Tertiary Care Referral Centers
@en
Rates of HCV Treatment Eligibi ...... Tertiary Care Referral Centers
@nl
altLabel
Rates of HCV treatment eligibi ...... tertiary care referral centers
@en
prefLabel
Rates of HCV Treatment Eligibi ...... Tertiary Care Referral Centers
@ast
Rates of HCV Treatment Eligibi ...... Tertiary Care Referral Centers
@en
Rates of HCV Treatment Eligibi ...... Tertiary Care Referral Centers
@nl
P2093
P2860
P921
P356
P1433
P1476
Rates of HCV Treatment Eligibi ...... Tertiary Care Referral Centers
@en
P2093
Adeel A Butt
Deborah McMahon
Joel Tsevat
Obaid S Shaikh
Uzma A Khan
Vincent Lo Re
Zachariah Dorey-Stein
P2860
P356
10.1310/HCT1001-025
P407
P577
2009-01-01T00:00:00Z